Table 1.

Cases with Alterations of Clinical Significance Identified by BAC and Oligo aCGH.

Pt. #	Chr	Band	Start pos.	End pos.	Gain/Loss	Size	# of BACs	# of Oligos
21637	chr16	p11.2	29,563,985	30,066,187	Loss	502,202	5	46
21992	chr16	p11.2	29,563,985	30,066,187	Loss	502,202	5	46
22013	chr16	p11.2	29,563,985	30,066,187	Loss	502,202	5	46
21993	chr10	q25.2q25.3	114,306,207	114,925,368	Loss	619,161	3	36
21756	chr2	q35	219,418,281	220,060,969	Loss	642,688	2	43
22002	chr2	q37.3	239,664,393	240,400,008	Loss	735,615	3	82
22334	chr10	q25.2q25.3	114,024,053	115,677,301	Gain	1,653,248	3	53
21688	chr16	p13.11p12.3	15,056,257	16,742,812	Gain	1,686,555	3	61
21667	chr17	p12	14,052,297	15,742,271	Gain	1,689,974	3	67
21896	chr4	q35.2	189,407,487	191,133,809	Loss	1,726,322	8	147
22269	chr2	q12.3q13	107,945,041	109,784,684	Loss	1,839,643	6	102
21640	chr19	q13.42	59,272,450	61,239,237	Gain	1,966,787	8	135
22117	chr9	q33.1	118,991,777	121,063,590	Gain	2,071,813	3	67
22066	chr8	p12p11.21	38,303,146	40,515,492	Gain	2,212,346	6	104
21786	chr1	q21.1	144,973,942	147,421,814	Gain	2,447,872	5	63
22237	chr1	q21.1	144,973,942	147,421,814	Gain	2,447,872	5	63
22310	chr22	q11.21	17,299,742	19,770,655	Loss	2,470,913	13	205
22050	chr22	q11.21	17,007,819	19,770,655	Loss	2,762,836	13	208
21936	chr1	q21.1	144,973,942	147,966,185	Gain	2,992,243	5	65
21719	chr2	q31.1	169,823,689	172,870,083	Loss	3,046,394	8	119
22128	chr4	q34.3	179,065,989	182,435,119	Loss	3,369,130	3	91
22006	chr17	p11.2	16,723,071	20,145,604	Loss	3,422,533	18	311
22174	chr1	q41q42.12	221,260,860	224,709,317	Loss	3,448,457	9	178
21971	chr22	q11.23q12.2	24,025,269	28,008,109	Loss	3,982,840	3	111
22073	chr15	q11.2q13.1	21,208,177	26,194,049	Loss	4,985,872	11	281
21687	chr16	q12.2q21	51,912,655	57,173,018	Loss	5,260,363	15	261
21975	chr5	p15.2p14.3	13,514,464	18,988,928	Loss	5,474,464	3	122
21555	chr7	p22.3p22.1	153,644	6,230,285	Gain	6,076,641	32	434
21547	chr2	q24.3q31.1	168,702,606	174,842,496	Loss	6,139,890	11	226
21755	chr11	p12p11.2	37,540,680	43,940,573	Loss	6,399,893	14	298
21761	chr3	p14.1p12.3	70,738,914	77,275,908	Loss	6,536,994	6	151
22151	chr15	q11.2q13.1	18,809,804	26,194,049	Gain	7,384,245	14	331
22322	chr8	p21.3p12	22,954,212	30,630,828	Loss	7,676,616	9	224
21889	chr2	q33.1q34	202,901,021	211,366,732	Gain	8,465,711	13	281
21723	chr5	q23.1q23.3	121,487,477	130,306,377	Loss	8,818,900	4	204
22337	chr1	p36.22p36.13	9,476,880	19,436,653	Loss	9,959,773	21	436
21795	chr1	p34.2p32.3	41,201,837	55,191,500	Gain	13,989,663	17	440
20986	chr12	p13.33p12.3	84,918	17,505,135	Gain	17,420,217	46	800
21957	chr11	q23.3q25	116,478,434	134,419,382	Gain	17,940,948	40	784
21596	chr1	q25.1q32.1	173,519,967	203,663,817	Gain	30,143,850	25	814
22055	chr3	p14.1p13	71,164,161	71,958,845	Loss	794,684	3	46
21566*	chr17	p13.2p13.1	6,081,457	6,904,679	Loss	823,222	3	14
21558	chr22	q13.33	48,567,185	49,517,230	Loss	950,045	6	54
21770	chr8	p23.3	202,505	1,411,517	Loss	1,209,012	5	96
22254	chr8	p23.2	2,604,280	3,966,809	Loss	1,362,529	9	140
21937	chr7	q11.23	72,404,049	73,771,409	Loss	1,367,360	10	158
21710	chr15	q13.2q13.3	28,741,818	30,186,356	Loss	1,444,538	3	64
21722	chr15	q13.2q13.3	28,741,818	30,226,376	Loss	1,484,558	3	65
21739	chr15	q13.2q13.3	28,741,818	30,226,376	Loss	1,484,558	3	65
21787	chr15	q13.2q13.3	28,741,818	30,226,376	Loss	1,484,558	3	65
21897*	chr5	p15.2	8,511,592	9,888,817	Gain	1,377,225	34	29
21884	chrX	q28	152,676,750	153,059,428	Gain	382,678	3	44
21592	chrX	p22.33q28	701	154,888,083	Gain	154,887,382	325	6888
22087	chrY	p11.32	262,578	57,715,879	Gain	57,453,301	49	49
22285	chrX	p21.1	31,759,551	31,830,811	Loss	71,260	2	11
22244	chr22	q13.33	49,342,961	49,514,486	Loss	171,525	2	56
*additional alterations identified by oligonucleotide aCGH.